Anti-HAV Monoclonal antibody, Clone 2992

In virtual environments, spatial discrepancies between visual and haptic scenes negatively impact user performance and experience. This paper shows how spatial discrepancies due to pose differences can occur in a haptic augmented virtuality system with an encountered-type haptic display. To mitigate this problem, we propose visual guidance, an algorithm that dynamically manipulates the visual scene to compensate for discrepancies. The effectiveness of this algorithm was verified in a pair of studies involving a button pressing task and spatial discrepancies between +/- 150 mm and +/- 40 degrees. Experimental results show that discrepant trials using the technique yield error rates and a number of speed peaks (representing the number of targeting movements) that are comparable to those attained in trials with zero spatial discrepancy. This result was also achieved without requiring a dedicated adaptation or training process, ensuring the algorithm can be used immediately by users. A pair of follow-up studies also indicates the algorithm has little impact on subjective ratings of simulator sickness, suggesting that sporadic use of the algorithm will not negatively affect user's experience of a virtual environment. We believe that the visual guidance algorithm presented in this paper can be used to create more useful and compelling experiences in various haptic training applications incorporating encountered-type haptic displays.

Biotin taken orally can interfere with some diagnostic immunoassays, including those for thyroid hormones, ferritin, and markers of infectious disease. Assays affected are ones that use streptavidin-biotin in their design. The goal of our study was to examine the effect of biotin concentrations of up to 1200 ng/mL on three serological assays performed on VITROS 3600 system, Immunoglobulin M (IgM) antibodies to hepatitis A virus (anti-HAV), total anti-HAV, and IgM antibodies to hepatitis B virus core antigen (anti-HBc), by spiking serum samples with variable amounts of biotin. No false-negative results were generated with either concentration of biotin for total anti-HAV (65/65). Likewise, biotin caused no false-positive IgM anti-HAV results (59/59) with either concentration of biotin; however, 6.7% false negativity was found for IgM anti-HAV when samples were spiked with 1200 ng/mL of biotin. Conversely, 100% false positivity (30/30) was produced by biotin interference in total anti-HAV negative specimens with both concentrations of biotin. False negativity rate was 87.5% in IgM anti-HBc positive samples when biotin levels were at 1200 ng/mL. These data show that individuals taking biotin-containing supplements may test false-positive in some serologic assays using streptavidin-biotin chemistries. Further studies are warranted to determine the extent of biotin interference resulting in false-positive and negative results and their impact, if any, on surveillance and diagnostic settings.